Competition | Regulation | Litigation
Blogs
05-09-2022
Agri, food and retail: more room for sustainability + focus on consumer law
Developments in the field of sustainability and consumer law reviewed. Read more >
01-09-2022
Investment Screening Bill and FDI: investors beware of low reporting thresholds
The main developments regarding the new Investments, Mergers and Acquisitions Security Screening Act, in particular the low reporting thresholds and specific regulations. Read more >
30-08-2022
No more waiting lists or additional contracting in mental healthcare? Not without the NZa enforcing the duty of care!
Why is proactive enforcement by the Dutch Healthcare Authority of the NZa’s duty of care of insurance companies crucial to the functioning of our healthcare system and necessary to eliminate waiting lists for e.g. mental healthcare providers? Read more >
26-08-2022
Mergers and acquisitions reviewable in new ways: will healthcare be an exception?
New paths to a filing and key changes in healthcare merger review. Read more >
14-07-2022
Five tips for information exchange in due diligence investigations and M&A transactions. What is and is not allowed under the cartel prohibition?
The exchange of information between companies as part of a merger or acquisition may be prohibited. This blog summarises the main points for attention. Read more >
28-06-2022
Adjustments to NZa merger test: more limited scope but more intensive review
The NZa will change its healthcare-specific merger test as of 1 July 2022 on three points. The changes are addressed in this blog. Read more >
22-06-2022
ACM and European Commission step up action against abuse of dominant position of pharmaceutical companies
ACM and the European Commission are focusing their attention on abuse of a dominant position in the pharmaceutical sector. This blog lists the lessons that pharmaceutical companies can learn from the supervision by ACM and the Commission. Read more >